CLINICAL TRIAL RECRUITMENT FOR ABBV-744 STUDY FUNDAMENTALS EXPLAINED

In Section A, participants will acquire distinctive doses and schedules of oral ABBV-744 tablet to recognize Protected dosing program. Supplemental members will be enrolled within the determined monotherapy dosign regimen. In Phase B, individuals will acquire oral ruxolitinib and ABBV-744 might be presented as "include-on" therapy. In Segment C, me